2023
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.Peer-Reviewed Original ResearchUterine serous carcinomaHuman epidermal growth factor receptor 2Uterine carcinosarcomaSerous carcinomaTraditional platinum-based chemotherapyEpidermal growth factor receptor 2Growth factor receptor 2Platinum-based chemotherapyOngoing clinical trialsRare histologic variantHER2 protein overexpressionAggressive metastatic potentialFactor receptor 2Distinct molecular profilesPreclinical evidenceUterine carcinomaHistologic variantsClinical trialsHER2 oncogeneReceptor 2Metastatic potentialCarcinomaMolecular profileMolecular targetsProtein overexpression
2022
In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Aminpour M, Cannariato M, Preto J, Safaeeardebili M, Moracchiato A, Doria D, Donato F, Zizzi E, Deriu M, Scheim D, Santin A, Tuszynski J. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022, 10: 51. DOI: 10.3390/computation10040051.Peer-Reviewed Original ResearchAnti-inflammatory pathwaySARS-CoV-2 virusAlpha 7 nicotinic acetylcholine receptorCholinergic anti-inflammatory pathwayAnti-viral effectsActivity of ivermectinNicotinic acetylcholine receptorsBiological mechanismsVagus nerveCytokine productionImmune cellsClinical studiesCD147 receptorViral penetrationAcetylcholine receptorsNeuronal tissueIvermectinMolecular targetsHigh affinitySpike glycoproteinPhysiological concentrationsMorbidityCOVID-19VirusReceptors